Abstract
GLUTAMATE is important in several forms of synaptic plasticity such as long-term potentiation, and in neuronal cell degeneration1,2. Glutamate activates several types of receptors, including a metabotropic receptor that is sensitive to trans-1-amino-cyclopenthyl-l,3-dicarboxylate, coupled to G protein(s) and linked to inositol phospholipid metabolism3–6. The activation of the metabotropic receptor in neurons generates inositol 1,4,5-trisphosphate, which causes the release of Ca2+ from intracellular stores and diacylglycerol, which activates protein kinase C7–9. In nerve terminals, the activation of presynaptic protein kinase C with phorbol esters enhances glutamate release10. But the presynaptic receptor involved in this protein kinase C-mediated increase in the release of glutamate has not yet been identified. Here we demonstrate the presence of a presynaptic glutamate receptor of the metabotropic type that mediates an enhancement of glutamate exocytosis in cerebrocortical nerve terminals. Interestingly, this potentiation of glutamate release is observed only in the presence of arachidonic acid, which may reflect that this positive feedback control of glutamate exocytosis operates in concert with other pre- or post-synaptic events of the glutamatergic neurotransmission that generate arachidonic acid. This presynaptic glutamate receptor may have a physiological role in the maintenance of long-term potentiation where there is an increase in glutamate release mediated by postsynaptically generated arachidonic acid11.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Collingridge, G. L. & Bliss, R. V. P. Trends Neurosci. 10, 288–293 (1987).
Choi, D. W. & Rothman, S. M. A. Rev. Neurosci. 13, 171–182 (1990).
Masu, M., Tanabe, Y., Tsuchida, K., Shigemoto, R. & Nakanishi, S. Nature 349, 760–765 (1991).
Schoepp, D., Bockaert, J. & Sladeczek, F. Trends pharmac. Sci. 11, 508–515 (1990).
Sugiyama, H., Ito, I. & Hirono, C. Nature 325, 531–533 (1987).
Nicoletti, F., Wroblewski, J. T., Fadda, E. & Costa, E. Neuropharmacology 27, 551–556 (1988).
Sladeczek, F., Pin, J.-P., Recasens, M., Bockaert, J. & Weiss, S. Nature 317, 717–719 (1985).
Murphy, S. N. & Miller, J. R. Proc. natn. Acad. Sci. U.S.A. 85, 8737–8741 (1988).
Manzoni, O. J. J. et al. Neurosci. Lett. 109, 146–151 (1990).
Barrie, A. P., Nicholls, D. G., Sánchez-Prieto, J., & Sihra, T. S. J. Neurochem. 57, 1398–1404 (1991).
Lynch, M. A., Errington, M. L. Bliss, T. V. P. Neuroscience 30, 693–701 (1989).
Palmer, E., Monaghan, D. T. & Cotman, C. W., Eur. J. Pharmac. 166, 585–587 (1989).
Castagna, M. et al. J. biol Chem. 257, 7847–7851 (1982).
Shinomura, T., Asaoka, Y., Yoshida, K. & Nishizuka, Y. Proc. natn. Acad. Sci. U.S.A. 88, 5149–5153 (1991).
Murakami, K. & Routtenberg, A. FEBS Lett. 192, 189–193 (1985).
Mayer, M. L. & Westbrook, G. L. Prog. Neurobiol, 28, 197–276 (1990).
Monaghan, D. T., Bridges, R. J. & Cotman, C. W. A. Rev. Pharmac. Toxic. 29, 365–402 (1989).
Schoepp, D. D., Jonshon, B. G., Salhoff, C. R. & Hillman, C. C. Soc. Neurosci. Abstr. 16, 618 (1990).
Honoré, T. et al. Science 241, 701–703 (1988).
Davies, J. A., Francis, A., Jones, A. W. & Watkings, J. C. Neurosci. Lett. 21, 77–82 (1981).
Schoepp, D. D. & Johnson, B. G. J. Neurochem. 53, 273–278 (1989).
Tibbs, G. R., Barrie, A. P., Van-Mieghem, F., McMahon, H. T. & Nicholls, D. G. J. Neurochem. 53, 1693–1699 (1989).
McMahon, H. T. & Nicholls, D. G. J. Neurochem. 56, 86–94 (1991).
Bliss, T. V. P., Douglas, R. M. Errington, M. L. & Lynch, M. A. J. Physiol. Lond. 377, 391–408 (1986).
Bliss, T. V. P. & Lynch, M. A. in Neurology and Neurobiology Vol. 35 (eds Landfield, P. W. & Deadwyler, S. W.) 3–72 (Liss, New York, 1988).
Herrero, I., Miras-Portugal, M. T. & Sánchez-Prieto, J. J. Neurochem. 57, 718–721 (1991).
Herrero, I., Miras-Portugal, M. T. & Sánchez-Prieto, J. FEBS Lett. 296, 317–319 (1992).
Nicholls, D. G. Biochem. J. 170, 511–522 (1978).
Herrero, I., Castro, E., Miras-Portugal, M. T. & Sánchez-Prieto, J. Neurosci Lett. 126, 41–44 (1991).
Rubio, I., Torres, M., Miras-Portugal, M. T. & Sánchez-Prieto, J. J. Neurochem. 57, 1159–1164 (1991).
Nicholls, D. G., Sihra, T. S. & Sánchez-Prieto, J. J. Neurochem. 47, 50–59 (1987).
Verhage, M., Besselsem, E., Lopes da Silva, F. H. & Ghijsen, W. E. J. M. J. Neurochem. 53, 1188–1194 (1989).
Grynkiewiccz, G., Poenie, M. & Tsien, R. Y. J. biol. Chem. 260, 3440–3450 (1985).
Sims, P. J., Waggoner, A. S., Wang, C. H. & Hoffman, J. F. Biochemistry 13, 3315–3330 (1974).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Herrero, I., Miras-Portugal, M. & Sánchez-Prieto, J. Positive feedback of glutamate exocytosis by metabotropic presynaptic receptor stimulation. Nature 360, 163–166 (1992). https://doi.org/10.1038/360163a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/360163a0
This article is cited by
-
Glutamate and Its Receptors as Therapeutic Targets for Migraine
Neurotherapeutics (2018)
-
Potentiation of excitatory serotonergic responses by MK-801 in the medial prefrontal cortex
Naunyn-Schmiedeberg's Archives of Pharmacology (2009)
-
Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme
Psychopharmacology (2008)
-
Functional interactions between presynaptic NMDA receptors and metabotropic glutamate receptors co‐expressed on rat and human noradrenergic terminals
British Journal of Pharmacology (2007)
-
Metabotropic glutamate receptors
Cell and Tissue Research (2006)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
